阿替普酶静脉溶栓后发生早期神经功能恶化的研究进展

Study on the early neurological deterioration after intravenous thrombolysis therapy with alteplase

急性缺血性卒中是最常见的卒中类型,到目前为止,阿替普酶是国际上唯一被批准的治疗该疾病的有效药物,但是部分溶栓患者临床症状并未改善,甚至还发生了早期神经功能恶化(END)。END在临床上并不少见,但END的定义并没有统一的概念,其流行病学、发病机制、危险因素等仍未完全明了。大量研究表示END的发生与患者的不良预后有着直接联系,所以预防和治疗END具有重要的意义。近年来上述问题一直是国内外众多学者讨论的热点,现就以上内容进行综述。

Acute ischemic stroke is the most common type of stroke. So far, alteplase is the only approved drug in the world to treat this disease. However, the clinical symptoms of some patients with thrombolysis have not improved, and even early neurological deterioration( END) has occurred. END is not uncommon in clinical practice, but the definition of END does not have a unified concept. Its epidemiology, pathogenesis, and risk factors are still not fully understood. A large number of studies have shown that the occurrence of END is directly related to the poor prognosis of patients, so prevention and treatment of END is of great significance. In recent years, the problems mentioned above have been the hotspots discussed by many scholars in China and abroad. The above contents are reviewed in this paper.